Epratuzumab Biosimilar, Anti-human CD22 Monoclonal Antibody | C046P

Catalog No.	C046P
Product Name	Epratuzumab Biosimilar, Anti-human CD22 Monoclonal Antibody | C046P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	cluster of differentiation-22, SIGLEC-2, SIGLEC2
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Source/Host	The anti-human CD22 monoclonal antibody epratuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade epratuzumab biosimilar specifically binds to the human CD22 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by epratuzumab.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade epratuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Epratuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C041P

C046P: Epratuzumab Biosimilar, Anti-human CD22 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab.

Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab’s predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

Please remember our product information: Epratuzumab Biosimilar, CD22 Monoclonal Antibody: C046P Syd Labs

No more offers for this product!